Objectives: To evaluate, in a clinical cohort of HIV-1-infected patients, the prevalence of PI minority resistant variants (MRV) at ART baseline and their impact on the virological response to a first-line PI-based regimen.
Introduction
Ultra-deep sequencing (UDS) allows detection of HIV quasi-species down to a proportion of 1%, compared with 20% with Sanger sequencing, i.e. standard genotyping technology.
A 2-or 3-fold increase in the prevalence of transmitted drug resistance (TDR) was observed in ART-naive patients when detecting minority resistant variants (MRV) using UDS. [1] [2] [3] Baseline MRV with NNRTI resistance-associated mutations (RAM) were found to be associated with a 2.5-to 3-fold increased risk of virological failure (VF) in patients initiating a first-line NNRTI-containing regimen. 4, 5 Thus, for NNRTI the presence of baseline MRV can jeopardize virological response.
Regarding PI, few studies have analysed baseline PI MRV impact on virological response to a first-line PI-containing regimen. Indeed, this is limited by the low number or lack of VF in the PI arms in clinical trials, leading to a lack of statistical power. Furthermore, the high genetic barrier of PI to resistance could limit the deleterious impact of MRV on virological response. In ART-naive patients initiating a first-line PI-containing regimen with atazanavir or lopinavir, baseline PI MRV prevalence was higher in patients with virological success than in patients with VF. 6 The aim of this study was to assess, in a clinical cohort of HIV-1-infected patients, the impact of PI MRV at ART baseline on virological response to a first-line PI-based regimen.
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Patients and methods

Study patients
In an observational single-centre cohort, we included all ART-naive patients initiating a first-line regimen including two NRTI and one boosted PI, darunavir/ritonavir or atazanavir/ritonavir, between January 2012 and March 2015. A VF was defined as two consecutive viral loads (VL) .50 copies/mL following VL ,50 copies/mL or as the absence of reaching VL ,50 copies/mL 6 months after ART initiation.
Ethics
All the patients gave their written informed consent to have their medical chart recorded in the electronic medical record system Nadis V R (www.dataids. org Fedialis Medica, Marly Le Roi, France, CNIL number: 1171457, 24 May 2006), designed for the healthcare medical follow-up of HIV-infected patients.
pol gene UDS HIV-1 RNA was extracted using EZI Virus Mini Kit v2.0 V R (Qiagen, Hilden, Germany) and amplified by PCR using SuperScript V R III One-Step RT-PCR System with Platinum V R Taq High Fidelity (Thermofisher, Waltham, MA, USA) with the primers Pan-HIV-1_2F (5 0 -GGGAAGTGAYATAGCWGGAAC) and PCRPOL-R (5 0 -TATGGAGACYCCMTGACC). 7 A 3385 bp fragment was then amplified by a second round of PCR using PrimeSTAR V R GXL DNA Polymerase Kit (Takara Bio Inc., Nojihigashi, Japan) with the primers NPCRPOL-F (5 0 -GACAGCATGYCAGGGAG) and NPCRPOL-R (5 0 -TGGGATRTGTACTTCTGARC). UDS was performed using Illumina Miseq V R technology (Illumina, San Diego, CA, USA). pol sequences were analysed using Geneious V R software (https:// www.geneious.com). 8 An MRV was defined as a variant harbouring RAM present between 1% and 20%. Each MRV was confirmed by visualization of reads alignment.
At VF, only the protease region was sequenced using the ANRS protocol (www.hivfrenchresistance.org).
Protease and RT resistance mutations were identified using the WHO TDR list 9 added to the IAS-USA list for PI major resistance mutations. 10 Integrase mutations were identified using the ANRS algorithm (version 26).
Statistical analyses
Fisher's exact tests were performed using R software.
Results
Study patients
pol gene UDS was successful in 110 samples among the 137 ARTnaive patients enrolled (80.3%), including 94 and 16 patients who initiated a darunavir/ritonavir-based regimen and an atazanavir/ ritonavir-based regimen, respectively. Median baseline VL and CD4 cell count were 5.03 log 10 copies/mL (IQR " 4.71-5.43) and 315/mm 3 (IQR " 143-411), respectively (Table 1) . Twenty-eight percent of the patients were infected with HIV-1 subtype B, 39% with CRF02_AG and 33% with other non-B subtypes.
Sanger sequencing evidenced TDR in eight patients (7.3%, 95% CI " 2.4-12.2). NRTI RAM were detected in five samples, including thymidine analogue mutations in all cases. NNRTI RAM were detected in five samples, with K103N in two cases. No TDR was detected for PI. All eight patients exhibited virological success.
Thirteen patients (13.8%) receiving a darunavir-based regimen and three (18.8%) receiving an atazanavir-based regimen experienced a VF, which occurred a median of 15.5 months following PI-based regimen initiation.
Prevalence of baseline protease MRV
Thirteen subjects (11.8%) had PI MRV at baseline of ART initiation. PI MRV were present in the median proportion of 1.3% (IQR " 1.1-1.7) and with a median mutational VL of 1445 copies/mL (IQR " 378-4336). The most prevalent PI MRV were G73C (n " 5, 4.5%), M46I (n " 3, 2.7%) and M46L (n " 2, 1.8%) ( Table 2) .
The proportion of patients harbouring baseline PI MRV was similar between those with virological success (n/N " 10/94, 10.6%) Perrier et al.
and those experiencing a VF (n/N " 3/16, 18.8%) (P " 0.40). One of the three patients with PI MRV experiencing a VF had the highest baseline VL (6.9 log 10 copies/mL) and the highest mutational load (4.9 log 10 copies of V32I/mL). Regarding the two other patients with PI MRV experiencing a VF, they displayed a mutational load close to the median or below. No differences were observed in the prevalence of PI MRV between patients infected with subtype B (n/N " 5/31, 16.1%) and those infected with CRF02_AG and other non-B subtypes (n/N " 8/79, 10.1%) (P " 0.51). No differences were observed in the prevalence of PI MRV between patients initiating a darunavir/ritonavir-based regimen (n/N " 10/94, 10.6%) or an atazanavir/ritonavir-based regimen (n/N " 3/16, 18.8%) (P " 0.40).
Prevalence of baseline RT and integrase MRV
Eighteen patients (16%) displayed baseline RT MRV in the median proportion of 1.9% (IQR " 1.4-5.2). NNRTI MRV were P225H (n " 7, 6.4%), L100I (n " 1, 0.9%) and K103S (n " 1, 0.9%). NRTI MRV were T215I (n " 3, 2.7%), T69S (n " 2, 1.8%) and D67N (n " 2, 1.8%).
Seventeen patients (15%) displayed baseline integrase MRV in the median proportion of 1.8% (IQR " 1.1-2.3). The most prevalent integrase MRV were S147G (n " 5, 4.5%), Q148H (n " 3, 2.7%) and L74I (n " 3, 2.7%).
The proportion of patients harbouring baseline NRTI, NNRTI and integrase MRV was similar between those with virological success or VF (n/N " 6/94 versus 3/16, P " 0.12; n/N " 7/94 versus 2/16, P " 0.62; and n/N " 15/94 versus 2/16, P " 1.00; respectively).
UDS protease at VF
The median VL at VF was 483 copies/mL (IQR " 378-4336). Among the 16 patients experiencing a VF, a plasma sample at VF was available in 13 and the protease region was successfully amplified in 10 (77%).
No major PI RAM was detected at VF in majority as well as in minority proportions. Three patients displayed emergence of secondary PI mutations at VF. In two cases, secondary mutations were present in minority proportions at baseline (L10I at 11% and L63P at 5%) and then present in 100% of the reads at VF. In one patient, I15V, H69K and L89M mutations, not detected in baseline samples even in a minority proportion, were detected at VF in a majority proportion.
Discussion
Among the 110 patients included in this study, the prevalence of PI MRV at ART initiation was 11.8%, with no difference between patients with virological success or failure.
The prevalence of baseline PI MRV found in our study is in a range similar to that previously described, ranging from 7.1% to 10.4%. 3, 6 One study showed a higher prevalence, with 19.5% of baseline PI MRV; however, the list of mutations was extended to all the Stanford algorithm mutations.
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In our study, we showed no significant impact of baseline PI MRV on virological response to a PI-based regimen both for atazanavir and darunavir drugs. Similarly, a sub-study of the CASTLE trial, assessing lopinavir and atazanavir, had shown the lack of deleterious impact of PI MRV on virological response since PI MRV prevalence was higher in patients with virological success than in patients with VF. 6 In the present study, we report for the first time data assessing the impact of baseline PI MRV on virological response to a darunavir/ritonavir-based regimen, the most recent and widely used PI.
The impact of baseline MRV on virological response was well described for the NNRTI drug class. 4, 5 Thus, the detection of baseline NNRTI MRV could be considered, especially in the case of high VL, to optimize therapeutic management of a first-line NNRTIbased regimen. On the contrary, our results suggest no need to perform baseline protease UDS in the case of a first-line PI-based regimen and reinforce the robustness of this class.
Previous studies have shown a direct dose-effect relationship between the mutational load of NNRTI MRV and the risk of VF. 4 In our study, the median mutational load of PI MRV was 1445 copies/mL. This level can be considered high, since a threshold of 2000 copies/mL for K103N NNRTI RAM was associated with an increased risk of VF. 12 In the present study, no emergence of major PI resistance mutations was observed at VF, as previously described with this drug class. 13, 14 Indeed, findings from randomized clinical trials and observational cohorts showed a very low rate of selection of PI RAM when failing a PI-based regimen. 13, 14 We observed emergence of secondary mutations in 3/10 cases, with no expected impact on the resistance level. In the CASTLE trial, some patients (8.3%) had virus with major PI MRV at low level at VF without impact on phenotypic resistance level. 15 This study was limited by the small sample size, the low proportion of patients receiving atazanavir and the low number of patients experiencing VF, which might preclude the observation of a significant impact of baseline PI MRV on virological outcome.
In conclusion, we showed a prevalence of 11.8% of PI MRV among 110 ART-naive subjects, without significant impact on virological response to a first-line PI-based regimen containing darunavir or atazanavir. HIV-1 protease minority resistant variants JAC
